JP2018538273A - 虚血性脳卒中を処置するための組成物および方法 - Google Patents

虚血性脳卒中を処置するための組成物および方法 Download PDF

Info

Publication number
JP2018538273A
JP2018538273A JP2018526571A JP2018526571A JP2018538273A JP 2018538273 A JP2018538273 A JP 2018538273A JP 2018526571 A JP2018526571 A JP 2018526571A JP 2018526571 A JP2018526571 A JP 2018526571A JP 2018538273 A JP2018538273 A JP 2018538273A
Authority
JP
Japan
Prior art keywords
cromolyn
compound
stroke
brain
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018526571A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018538273A5 (enExample
Inventor
デイビッド エルマレ，
デイビッド エルマレ，
Original Assignee
エーゼットセラピーズ， インコーポレイテッド
エーゼットセラピーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エーゼットセラピーズ， インコーポレイテッド, エーゼットセラピーズ， インコーポレイテッド filed Critical エーゼットセラピーズ， インコーポレイテッド
Publication of JP2018538273A publication Critical patent/JP2018538273A/ja
Publication of JP2018538273A5 publication Critical patent/JP2018538273A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018526571A 2015-11-23 2016-11-23 虚血性脳卒中を処置するための組成物および方法 Pending JP2018538273A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562258882P 2015-11-23 2015-11-23
US62/258,882 2015-11-23
PCT/US2016/063462 WO2017091644A1 (en) 2015-11-23 2016-11-23 Compositions and methods for treating ischemic stroke

Publications (2)

Publication Number Publication Date
JP2018538273A true JP2018538273A (ja) 2018-12-27
JP2018538273A5 JP2018538273A5 (enExample) 2020-01-09

Family

ID=58764360

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018526571A Pending JP2018538273A (ja) 2015-11-23 2016-11-23 虚血性脳卒中を処置するための組成物および方法

Country Status (9)

Country Link
US (2) US20180344682A1 (enExample)
EP (1) EP3380095B1 (enExample)
JP (1) JP2018538273A (enExample)
KR (1) KR20180081812A (enExample)
CN (1) CN108472275A (enExample)
AU (1) AU2016359674A1 (enExample)
CA (1) CA3005909A1 (enExample)
MX (1) MX390748B (enExample)
WO (1) WO2017091644A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019524865A (ja) * 2016-08-31 2019-09-05 ザ ジェネラル ホスピタル コーポレイション 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN104869993B (zh) 2012-10-25 2019-01-15 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN111565711B (zh) 2017-07-20 2023-01-03 阿茨治疗股份有限公司 色甘酸钠和布洛芬的粉末化制剂
CN111629719A (zh) * 2017-12-04 2020-09-04 通用医疗公司 色甘酸组合物及其方法
AU2019251191A1 (en) * 2018-04-09 2020-10-29 The General Hospital Corporation Combination therapies for the treatment of amyotropic lateral sclerosis and related disorders
KR20210071943A (ko) 2018-07-02 2021-06-16 더 제너럴 하스피탈 코포레이션 크로몰린 소듐 및 α-락토스의 분말화된 제형
US12383528B2 (en) 2018-12-10 2025-08-12 The General Hospital Corporation Cromolyn esters and uses thereof
WO2021207060A1 (en) 2020-04-06 2021-10-14 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
US12612391B2 (en) 2020-12-28 2026-04-28 The General Hospital Corporation Cromolyn derivatives and uses thereof
WO2025235823A1 (en) * 2024-05-08 2025-11-13 The Johns Hopkins University Compositions and methods for treatment of neuronal injury and neurode generative disorders

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012516356A (ja) * 2009-01-29 2012-07-19 ザ ジェネラル ホスピタル コーポレイション クロモリン誘導体、クロモリン誘導体を用いた治療方法及び造影方法
WO2014066318A1 (en) * 2012-10-25 2014-05-01 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US20140140927A1 (en) * 2009-01-29 2014-05-22 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2015002703A1 (en) * 2013-05-23 2015-01-08 Aztherapies, Inc Methods for delivering cromolyn
WO2015061397A1 (en) * 2013-10-22 2015-04-30 The General Hostpital Corporation Cromolyn derivatives and related methods of imaging and treatment
US20150224077A1 (en) * 2014-02-10 2015-08-13 Patara Pharma, LLC Methods for the Treatment of Systemic Disorders Treatable with Mast Cell Stabilizers, including Mast Cell Related Disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071531A1 (en) 2003-02-13 2004-08-26 Licentia Oy Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
ES2339790T3 (es) * 2004-08-30 2010-05-25 Seo Hong Yoo Efecto neuroprotector de udca solubilizado en modelo isquemico focal.
NZ594514A (en) * 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
AR076105A1 (es) * 2009-03-11 2011-05-18 Plexxikon Inc Derivados pirrol[2,3-b]piridina para inhibir la raf quinasa
US20190240194A1 (en) * 2016-08-31 2019-08-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012516356A (ja) * 2009-01-29 2012-07-19 ザ ジェネラル ホスピタル コーポレイション クロモリン誘導体、クロモリン誘導体を用いた治療方法及び造影方法
US20140140927A1 (en) * 2009-01-29 2014-05-22 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2014066318A1 (en) * 2012-10-25 2014-05-01 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
WO2015002703A1 (en) * 2013-05-23 2015-01-08 Aztherapies, Inc Methods for delivering cromolyn
WO2015061397A1 (en) * 2013-10-22 2015-04-30 The General Hostpital Corporation Cromolyn derivatives and related methods of imaging and treatment
US20150224077A1 (en) * 2014-02-10 2015-08-13 Patara Pharma, LLC Methods for the Treatment of Systemic Disorders Treatable with Mast Cell Stabilizers, including Mast Cell Related Disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, vol. 26, JPN6020035969, 2006, pages 605 - 612, ISSN: 0004726787 *
PHARMACOLOGY, vol. 92, JPN6020035966, 2013, pages 324 - 334, ISSN: 0004726786 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019524865A (ja) * 2016-08-31 2019-09-05 ザ ジェネラル ホスピタル コーポレイション 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア
JP2022171666A (ja) * 2016-08-31 2022-11-11 ザ ジェネラル ホスピタル コーポレイション 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア

Also Published As

Publication number Publication date
MX2018006390A (es) 2019-02-14
US20220125753A1 (en) 2022-04-28
MX390748B (es) 2025-03-21
US20180344682A1 (en) 2018-12-06
CN108472275A (zh) 2018-08-31
WO2017091644A1 (en) 2017-06-01
EP3380095A4 (en) 2019-10-23
AU2016359674A1 (en) 2018-06-14
EP3380095B1 (en) 2022-01-05
KR20180081812A (ko) 2018-07-17
EP3380095A1 (en) 2018-10-03
CA3005909A1 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
EP3380095B1 (en) Compositions and methods for treating ischemic stroke
US20250017875A1 (en) Stable cannabinoid formulations
US20220054450A1 (en) Stable cannabinoid formulations
JP2025118786A (ja) 安定なカンナビノイド製剤
US12544389B2 (en) Stable cannabinoid formulations
CN117377476B (zh) 治疗与化学疗法诱发的周围神经病变相关的疼痛
TW201505634A (zh) 藥物戒斷之無毒治療方法
BR112020016500A2 (pt) Agente preventivo ou terapêutico e composição farmacêutica para doença inflamatória ou doença óssea
US20250025444A1 (en) Treatment of neurodegenerative diseases via administration of buntanetap and a phosphodiesterase inhibitor
JP7849574B2 (ja) ゴーシェ病を処置するためのアリモクロモル
JP6068447B2 (ja) 過活動膀胱の治療のためのソリフェナシンと唾液分泌刺激剤の組合せ
RU2485956C2 (ru) Новая композиция для лечения побочных эффектов противораковой терапии
KR20260021653A (ko) IgA 매개 질환의 치료 방법에 사용하기 위한 스파르센탄
TW202220650A (zh) 5-甲基-1,2,4-噁二唑-3-基化合物之低劑量療法及調配物
JP7257091B2 (ja) 認知症の治療及び予防薬
TWI794847B (zh) 用於減少代謝症候群之組合物及其應用
Jonassen et al. AP1189: A novel oral biased melanocortin agonist with anti-inflammatory and pro-resolving effect for the treatment of rheumatoid arthritis—ACR meeting abstracts
EA052714B1 (ru) Фармацевтическая композиция, содержащая производные дифенилдиазола, и способ применения
US20120028976A1 (en) Pharmacokinetically-based dosing regiments of a thrombin receptor antagonist
Cutler et al. Pharmacokinetics and pharmacodynamics of avitriptan in patients with migraine after oral dosing
AU2024337440A1 (en) Cannabinoid for use in treating eye disorders
HK40090895B (en) Arimoclomol for treating gaucher disease
HK40090895A (en) Arimoclomol for treating gaucher disease
KR20240128504A (ko) 산 펌프 억제 활성을 갖는 신규 벤즈이미다졸 유도체
HK40084518B (en) Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191122

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200910

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200925

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211202

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220315